+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

04 June 2019
Pharma

Visiongain has published a new pharma report Global Antifungal Drugs Market Report : Azoles, Echinocandins, Polyenes, Allylamines, Voriconazole, Posaconazole, Clotrimazole, Isavuconazole, Fluconazole, Caspofungin, Micagunfin, Amphotericin, Lamisil, Dermatophytosis, Aspergillosis, Candidiasis.

The global antifungal drugs market is estimated to have reached $14bn in 2018 and is expected to grow at a CAGR of 3.8% during the forecast period. In 2018, the global antifungal drugs market was dominated by Azoles.

This report profiled the selected companies: Abbott Laboratories, Bayer AG, Enzon Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Kramer Laboratories, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Sanofi S.A. and others.

The lead analyst commented that "Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

The antifungal drugs market is mainly driven by the incidence and prevalence rate of antifungal infections. Moreover, cost-effective products, growing population of immunocompromised individuals and minimal side-effects are other factors that will drive market growth. However, antifungal drugs market has some restraints such as the presence of alternative therapies."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read